Leishmaniasis

Infection happens after the bite of an infected sandfly carrying Leishmania parasites. Doctors distinguish between risk factors you can change and those you can’t. Risk of leishmaniasis is higher if you live or travel in endemic areas, spend evenings outdoors without protection, or sleep in homes without screens or bed nets. Deforestation, conflict, and climate shifts can bring sandflies closer to people and widen where leishmaniasis occurs. Weak immunity from HIV, medicines, or malnutrition raises risk, and certain genes and parasite species can shape which early symptoms of leishmaniasis show up.

Genetic risk factors

Genes can shape how your immune system recognizes and controls Leishmania. Researchers have identified several genetic risk factors for leishmaniasis that influence who develops infection and who progresses to severe forms. Some risk factors are inherited through our genes. Differences in the parasite’s own genes can also affect how aggressive an infection becomes.

• HLA class II: Small differences in HLA class II genes can change how your immune system shows Leishmania to T cells. Certain versions are linked to higher risk of visceral leishmaniasis in some regions.

• SLC11A1 (NRAMP1): This macrophage gene helps control minerals that microbes need inside immune cells. Variants can weaken parasite-killing and raise the chance of persistent infection.

• IL-10 variants: IL-10 is a calming immune signal that can dial down inflammation. Versions that increase IL-10 activity are associated with more severe or long-lasting leishmaniasis.

• IFN-γ/IL-12 axis: These immune messengers drive parasite-killing responses by activating macrophages. Inherited changes that reduce this pathway can raise susceptibility or make disease harder to clear.

• TNF gene variants: TNF helps immune cells contain infection and form protective structures around it. Variants that lower TNF signaling may increase risk or worsen outcomes.

• Toll-like receptors: TLR genes help immune cells recognize parasite components early on. Genetic differences can alter this first alarm, shifting the odds of cutaneous versus visceral disease.

• Family history: Clustering of leishmaniasis in some families points to shared inherited susceptibility. This pattern has been observed in multiple populations.

• Primary immunodeficiencies: Rare, single-gene conditions affecting the IL-12/IFN-γ pathway can lead to severe or recurrent leishmaniasis. Examples include defects in IL12RB1 or IFNGR1.

• Parasite strain genes: Genetic differences between Leishmania species and strains influence how aggressive infection is and which organs are involved. Certain strain-specific gene changes are linked to treatment response and severity.

Transmission

Leishmaniasis spreads mainly through the bite of an infected sand fly, which picks up the parasite when it feeds on an infected human or animal. It is not spread by casual contact, coughing, kissing, or sharing food; in most settings leishmaniasis is not contagious from person to person without a sand fly. Rarely, the parasite can be passed through blood transfusion or organ transplant, from pregnancy to baby, or through needle sharing. In some regions, dogs and wild mammals act as reservoirs, so how leishmaniasis spreads locally depends on whether sand flies feed mostly on people or on animals. In the United States and much of Europe, human infections are uncommon and usually travel-related, and overall the condition is not considered highly infectious because a sand fly is almost always required for transmission.

When to test your genes

Leishmaniasis is an acquired infection, so genetic testing isn’t used to detect it or guide routine care. Consider genetic testing only if a clinician suspects a rare immune disorder that increases susceptibility to severe infections. Otherwise, diagnosis relies on exposure history, exam, and parasite testing, not your DNA.

Looking at the long-term picture can be helpful. For most people with leishmaniasis, the outlook depends on the type—cutaneous (skin), mucocutaneous (skin and mucous membranes), or visceral (internal organs)—and how quickly treatment starts. Early symptoms of leishmaniasis can be subtle, like a painless skin sore or weeks of fever and weight loss, so delays in care sometimes happen. Early care can make a real difference, especially for visceral leishmaniasis, which can be life-threatening without treatment but is often curable with the right medicines.

Cutaneous leishmaniasis usually isn’t life-threatening and often heals over months, though scars can remain. Mucocutaneous disease can appear months to years after skin lesions and may damage the nose or mouth if not treated; with prompt therapy, many people prevent lasting harm. Visceral leishmaniasis (kala-azar) involves the spleen, liver, and bone marrow; without treatment, mortality is high, but with modern drugs, survival rates are strong and most people improve within weeks.

Prognosis refers to how a condition tends to change or stabilize over time. The long-term outlook also reflects where someone lives, nutrition, immune health (including HIV status), and access to effective medicines. Relapse can occur, particularly in people with weakened immunity, but follow-up visits help catch problems early. Talk with your doctor about what your personal outlook might look like.

Treatment for leishmaniasis depends on the form (skin, mucosal, or visceral), the species, and where the infection was acquired, so doctors tailor therapy to each person’s situation. Visceral leishmaniasis usually needs prompt prescription medicines such as liposomal amphotericin B given by vein, or oral miltefosine where available; some regions also use antimonial drugs or combination regimens based on local resistance patterns. Skin leishmaniasis may be treated with local care (wound care, sometimes heat or cold therapy) or medicines applied to the lesion, but deeper, larger, facial, or multiple lesions often require systemic drugs similar to those for visceral disease. People with mucosal leishmaniasis typically receive systemic therapy and careful follow‑up to prevent tissue damage and relapse, and supportive care can make a real difference in how you feel day to day. Alongside medical treatment, lifestyle choices play a role, including nutrition, rest, and avoiding further sand fly exposure; ask your doctor about the best starting point for you.

Genes don’t cause leishmaniasis—exposure to infected sand fly bites does—but inherited differences in the immune system can influence how your body responds once the parasite is introduced. Having a genetic risk is not the same as having the disease itself. Research suggests that small variations in immune-related genes can affect genetic susceptibility to leishmaniasis, shaping who clears the parasite quickly and who is more likely to develop severe illness such as visceral leishmaniasis. These effects vary across populations, and environment and bite exposure remain the biggest drivers of who develops leishmaniasis. Parasite genetics play a role, too: different Leishmania species and even strains are linked with skin-limited versus internal-organ disease and can influence how well certain treatments work. For most people, this information guides prevention and care rather than testing; avoiding sand fly bites, seeking early evaluation after exposure, and timely treatment make the largest difference while science continues to clarify which gene patterns raise risk.

Leishmaniasis can interact strongly with other illnesses, especially conditions that affect the immune system. Doctors call it a “comorbidity” when two conditions occur together. When leishmaniasis and HIV occur together, the infection often lasts longer, comes back more often, and can show up in unusual ways; in turn, active leishmaniasis may make it harder to control HIV. People on immune-suppressing medicines after an organ transplant, during cancer treatment, or for autoimmune diseases face a higher risk of severe or reactivated leishmaniasis and may need closer monitoring. Early symptoms of leishmaniasis like fever, night sweats, weight loss, and anemia can look a lot like malaria or tuberculosis, which can delay the right diagnosis in places where several infections are common. Malnutrition can worsen leishmaniasis, and during pregnancy the disease may be more severe and, rarely, pass to the baby, so prompt treatment and specialist input matter. Because some leishmaniasis medicines can affect the heart or kidneys and may interact with HIV or tuberculosis treatments, make sure your care team coordinates medications across all your conditions.

How genes can cause diseases

Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.

Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.